AIMA
PFE icon

Ables Iannone Moore & Associates’s Pfizer PFE Stock Holding History

Ables Iannone Moore & Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,353
Closed -$39K – 229
2023
Q4 		$39K Buy
+1,353
New +$40.9K 0.03% 108

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ables Iannone Moore & Associates's PFE Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of Pfizer (PFE) in Q1 2024, closing a stake of 1,353 shares — an estimated $39K sold.

Ables Iannone Moore & Associates first reported a position in PFE in Q4 2023 and held it in 1 quarter. The position peaked at $39K in Q4 2023. 2,875 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

  • Ables Iannone Moore & Associates reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
  • Ables Iannone Moore & Associates sold 1,353 Pfizer shares in Q1 2024, an estimated $39K.
  • Ables Iannone Moore & Associates first reported a position in Pfizer in Q4 2023 and held it in 1 quarter.
  • Ables Iannone Moore & Associates's Pfizer position peaked at $39K in Q4 2023.
  • 2,875 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.